Patient population
| . | All patients, no. (N = 177) . | Patients expressing all 5 myeloid markers, no. (n = 50) . | Patients expressing 1-4 myeloid markers, no. (n = 127) . | P . |
|---|---|---|---|---|
| Age, y, mean/range | 57/18-82 | 51 ± 15 | 60 ± 16 | .05* |
| WHO PS < 2, n | 133 | 44 | 89 | NS* |
| WBC at diagnosis, ×109 cells per L, mean/range | 50/0.3-525 | 68 ± 60 | 39 ± 58 | NS* |
| LDH, U/L, mean/range | 1803/257-15 000 | 1740 ± 1362 | 1853 ± 1990 | NS* |
| FAB morphology, n (% of total) | .03† | |||
| M0 | 4 (2) | 0 | 4 | |
| M1 | 35 (20) | 12 | 22 | |
| M2 | 63 (36) | 16 | 47 | |
| M4 | 35 (20) | 15 | 20 | |
| M4E | 7 (4) | 4 | 3 | |
| M5 | 25 (14) | 3 | 22 | |
| M6 | 7 (4) | 0 | 7 | |
| M7 | 1 (<1) | 0 | 1 | |
| Karyotype, n (% of total) | .003† | |||
| Good prognosis, n | 22 (13) | 10 | 12 | |
| Inv(16) | 7 | 4 | 3 | |
| t(8;21) | 15 | 6 | 9 | |
| Intermediate prognosis | 113 (63) | 35 | 78 | |
| No abnormality | 78 | 25 | 53 | |
| +8 | 15 | 5 | 10 | |
| 11q23 | 6 | 1 | 5 | |
| Other abnormalities | 14 | 4 | 10 | |
| Unfavorable prognosis | 32 (22) | 2 | 30 | |
| Complex | 10 | 0 | 10 | |
| −7 | 9 | 0 | 9 | |
| Del(5q) or −5 | 8 | 2 | 6 | |
| Abn(3q) | 5 | 0 | 5 | |
| Failure or not done | 10 (6) | 1 | 9 | |
| Pgp expression, mean | 0.15 ± 0.09 | 0.11 ± 0.07 | 0.19 ± 0.12 | NS* |
| Pgp activity, mean (n = 150) | 0.42 ± 0.19 | 0.37 ± 0.19 | 0.52 ± 0.21 | .05* |
| In vitro sensitivity to DNR, μmol/L (n = 90)‡ | 0.53 ± 0.41 | 0.27 ± 0.27 | 0.78 ± 0.72 | .04* |
| In vitro sensitivity to AraC, μmol/L (n = 90)‡ | 13.4 ± 8.5 | 8.5 ± 5.7 | 17.9 ± 16.4 | .04* |
| . | All patients, no. (N = 177) . | Patients expressing all 5 myeloid markers, no. (n = 50) . | Patients expressing 1-4 myeloid markers, no. (n = 127) . | P . |
|---|---|---|---|---|
| Age, y, mean/range | 57/18-82 | 51 ± 15 | 60 ± 16 | .05* |
| WHO PS < 2, n | 133 | 44 | 89 | NS* |
| WBC at diagnosis, ×109 cells per L, mean/range | 50/0.3-525 | 68 ± 60 | 39 ± 58 | NS* |
| LDH, U/L, mean/range | 1803/257-15 000 | 1740 ± 1362 | 1853 ± 1990 | NS* |
| FAB morphology, n (% of total) | .03† | |||
| M0 | 4 (2) | 0 | 4 | |
| M1 | 35 (20) | 12 | 22 | |
| M2 | 63 (36) | 16 | 47 | |
| M4 | 35 (20) | 15 | 20 | |
| M4E | 7 (4) | 4 | 3 | |
| M5 | 25 (14) | 3 | 22 | |
| M6 | 7 (4) | 0 | 7 | |
| M7 | 1 (<1) | 0 | 1 | |
| Karyotype, n (% of total) | .003† | |||
| Good prognosis, n | 22 (13) | 10 | 12 | |
| Inv(16) | 7 | 4 | 3 | |
| t(8;21) | 15 | 6 | 9 | |
| Intermediate prognosis | 113 (63) | 35 | 78 | |
| No abnormality | 78 | 25 | 53 | |
| +8 | 15 | 5 | 10 | |
| 11q23 | 6 | 1 | 5 | |
| Other abnormalities | 14 | 4 | 10 | |
| Unfavorable prognosis | 32 (22) | 2 | 30 | |
| Complex | 10 | 0 | 10 | |
| −7 | 9 | 0 | 9 | |
| Del(5q) or −5 | 8 | 2 | 6 | |
| Abn(3q) | 5 | 0 | 5 | |
| Failure or not done | 10 (6) | 1 | 9 | |
| Pgp expression, mean | 0.15 ± 0.09 | 0.11 ± 0.07 | 0.19 ± 0.12 | NS* |
| Pgp activity, mean (n = 150) | 0.42 ± 0.19 | 0.37 ± 0.19 | 0.52 ± 0.21 | .05* |
| In vitro sensitivity to DNR, μmol/L (n = 90)‡ | 0.53 ± 0.41 | 0.27 ± 0.27 | 0.78 ± 0.72 | .04* |
| In vitro sensitivity to AraC, μmol/L (n = 90)‡ | 13.4 ± 8.5 | 8.5 ± 5.7 | 17.9 ± 16.4 | .04* |
Values are expressed as the mean plus or minus SE. The Pvalue indicates the comparison of a patient group with the presence of all 5 myeloid markers and a group with the absence of one or several myeloid markers. The normal value of LDH is less than 618 U/L. NS indicates not significant. Del indicates chromosome deletion, and Abn indicates abnormal chromosome. DNR indicates daunorubicin and AraC, cytosine arabinoside.
Indicates that the Mann-Whitney U test was used.
Indicates that the Fisher exact test was used.
Indicates that the MTT assay was used.